Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.
Journal article
Ni T. et al, (2023), iScience, 26
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Journal article
Port JR. et al, (2023), Nature communications, 14
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Journal article
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Journal article
Kaplonek P. et al, (2023), Nature immunology
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.
Journal article
Hotez PJ. et al, (2023), BMJ global health, 8
Factors, enablers and challenges for COVID-19 vaccine development.
Journal article
Excler J-L. et al, (2023), BMJ global health, 8
Vaccine access, equity and justice: COVID-19 vaccines and vaccination.
Journal article
Privor-Dumm L. et al, (2023), BMJ global health, 8
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
Preprint
Zhang P. et al, (2023)
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Journal article
Koen AL. et al, (2023), Vaccine, 41, 3486 - 3492
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model
Journal article
Saunders JE. et al, (2023), eBioMedicine, 90, 104523 - 104523
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Journal article
Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Journal article
Madhi SA. et al, (2023), The Lancet. Infectious diseases, 23, 295 - 306
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Journal article
Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
Journal article
McMahon WC. et al, (2023), AIDS (London, England), 37, 105 - 112
Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters.
Journal article
Port JR. et al, (2022), bioRxiv
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
Preprint
Flaxman A. et al, (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
Preprint
Emary KRW. et al, (2021)
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
Journal article
Voysey M. et al, (2021), SSRN Electronic Journal
CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells.
Journal article
Brenna E. et al, (2020), Cell reports, 30, 137 - 152.e5